A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
← catalyst calendarNCT06855771 · readout in 863 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
130estimated
Sites
70
Countries
Australia, China, France +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-09 | actual | When the study began enrolling |
| Primary completion | 2028-12-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Non-Small-Cell Lung
Intervention
- Drug: BMS-986504 — also filed as MRTX1719, Navlimetostat
Primary outcome
what the primary-completion date above is the date OFNumber of participants who achieve Objective Response (OR) utilizing the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
measured Up to 3 years after the last participant's last dose of study treatment
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed